Global Blood Therapeutics, Inc. (NASDAQ:GBT)
Industry: Healthcare

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.

Current Quote*
Last: $68.485
Change: 0.000
Book: $10.187
Volume: 884,751

As Of: 10/04 13:05 ET
*Quotes delayed by 20min.

BuyIns.Net Alerts for Symbol GBT

  • No BuyIns.Net Alerts Available for GBT

Graphs for GBT


3 Month Graph


6 Month Graph


1 Year Graph